Assessment and Management of Cardiovascular Disease Risk in Rheumatoid Arthritis Quiz
Author and Disclosure Information [Show]

From the Department of Medicine, Division of Rheumatology, Drexel University College of Medicine, Philadelphia, PA

DISCLOSURES: The authors have no financial relationships to disclose.

Click here to access the full article.

Question 1 of 5

A 50-year-old Caucasian man with a past medical history significant for rheumatoid arthritis (RA) and hypertension presents to his primary care physician’s office for his yearly physical. He has a 10-year history of hypertension and is on lisinopril 10 mg daily. He has a 15-year history of seropositive RA with erosive changes on radiographs. He is taking methotrexate 20 mg weekly along with folic acid 1 mg daily with good control of his arthritic symptoms. On his most recent rheumatology visit, he was noted to have a clinical disease activity index (CDAI) of 6, suggestive of low disease activity.

On physical examination, his vital signs are: heart rate, 74 beats/min; blood pressure, 120/80 mm Hg; respiratory rate, 16 breaths/min. He is afebrile. Body mass index (BMI) is 25.6 kg/m2.

The results of the patient’s most recent lipid panel are: total cholesterol (TC), 150 mg/dL (reference, < 200); high-density lipoprotein (HDL) cholesterol, 45 mg/dL (reference, > 40); low-density lipoprotein (LDL) cholesterol, 100 mg/dL (reference, 100); triglycerides 130 mg/dL (reference, 150).

He does not have a history of diabetes and is a lifetime nonsmoker. His 10-year atherosclerotic cardiovascular disease (CVD) risk score is 3.1%.

What would be the most appropriate step in minimizing his overall cardiovascular morbidity and mortality risk?

Add a β-blocker

Add a nonsteroidal anti-inflammatory drug

Add a statin

Add a tumor necrosis factor inhibitor

This quiz is not accredited for CME.

More from Rheumatology News Board Review Quizzes

QUIZ

Neuropsychiatric Manifestations of Systemic Lupus Erythematosus Quiz
Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Assessment and Management of Cardiovascular Disease Risk in Rheumatoid Arthritis